Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Canan John

2. Date of Event Requiring Statement (MM/DD/YYYY) 4/1/2020

3. Issuer Name and Ticker or Trading Symbol

Acasti Pharma Inc. [ACST]

(Last) (First) (Middle)

C/O ACASTI PHARMA INC., 545 PROMENADE DU CENTROPOLIS, SUITE 100

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

LAVAL, A8 H7T 0A3

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	100000	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (Right to Buy)	⁽¹⁾	2/24/2027	Common Shares	50000	$1.65 ⁽⁸⁾	D
Share Option (Right to Buy)	⁽²⁾	6/14/2027	Common Shares	17400	$1.77 ⁽⁸⁾	D
Share Option (Right to Buy)	⁽³⁾	6/14/2027	Common Shares	11600	$1.77 ⁽⁸⁾	D
Share Option (Right to Buy)	⁽⁴⁾	7/2/2028	Common Shares	60283	$0.77 ⁽⁸⁾	D
Share Option (Right to Buy)	⁽⁵⁾	4/15/2029	Common Shares	13300	$1.28 ⁽⁸⁾	D
Share Option (Right to Buy)	⁽⁶⁾	4/15/2029	Common Shares	45400	$1.28 ⁽⁸⁾	D
Share Option (Right to Buy)	⁽⁷⁾	3/31/2030	Common Shares	86000	$0.53 ⁽⁸⁾	D
Warrants	2/21/2017	2/21/2022	Common Shares	17500	$2.15 ⁽⁸⁾	D

Explanation of Responses:
(1)	Represents 50,000 common shares underlying 50,000 share options granted on February 24, 2017. These share options vested in 6 equal installments on a quarterly basis starting from February 24, 2017 until August 24, 2018.
(2)	Represents 17,400 common shares underlying 17,400 share options granted on June 14, 2017. These share options vested in 6 equal installments on a quarterly basis starting from June 14, 2017 until December 14, 2018.
(3)	Represents 11,600 common shares underlying 11,600 share options granted on June 14, 2017. These share options vested in 6 equal installments on a quarterly basis starting from June 14, 2017 until June 14, 2018.
(4)	Represents 60,283 common shares underlying 60,283 share options granted on July 2, 2018. These share options vested in 6 equal installments on a quarterly basis starting from July 2, 2018 until January 2, 2020.
(5)	Represents 13,300 common shares underlying 13,300 share options granted on April 15, 2019. These share options vest in 6 equal installments on a quarterly basis starting from April 15, 2019 until October 15, 2020.
(6)	Represents 45,400 common shares underlying 45,400 share options granted on April 15, 2019. These share options vest in 6 equal installments on a quarterly basis starting from April 15, 2019 until October 15, 2020.
(7)	Represents 86,000 common shares underlying 86,000 share options granted on March 31, 2020. These share options vest in 12 equal installments on a monthly basis starting from March 31, 2020 until March 31, 2021.
(8)	Canadian dollars.

Remarks:
Exhibit List - Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Canan John C/O ACASTI PHARMA INC. 545 PROMENADE DU CENTROPOLIS, SUITE 100 LAVAL, A8 H7T 0A3	X